#SFHS2615417VPatient Co-Payment Rate Set for OMLYCLO 300 mg
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
🇬🇧 English
The insured patient co-payment rate for OMLYCLO 300 mg, an injectable omalizumab medicine supplied in a pre-filled pen by Celltrion Healthcare France, is set at 35%.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Sets the insured patient co-payment rate for OMLYCLO 300 mg at 35%
- Applies to the listed pre-filled pen presentation of omalizumab
- Identifies Celltrion Healthcare France SAS as the laboratory for the product
Obligations
What this law requires
medium
Apply a 35% insured patient co-payment rate to OMLYCLO 300 mg (omalizumab) injectable solution, 2 ml, in pre-filled pen, CIP code 34009 303 393 3 6.
French health insurance fundspharmacies dispensing reimbursable medicines
From the decision dated 5 June 2026
operational
Affected Parties
insured patients using OMLYCLO 300 mgpharmacies and healthcare billing teams+1 more…
Tags
pharmaceuticals,patient co-payment,omalizumab